Last updated: July 31, 2026
Tybost, the brand name for cobicistat, is an FDA-approved pharmacokinetic enhancer used to increase systemic exposure to atazanavir or darunavir in adults with HIV-1 infection. Its commercial role is concentrated in combination regimens rather than standalone treatment. Cobicistat is also embedded in Gilead’s fixed-dose HIV products, including Stribild, Genvoya and Symtuza. Clinical development has largely shifted from standalone Tybost to complete antiretroviral combinations and treatment simplification.
Standalone Tybost faces limited growth because cobicistat is not an antiretroviral agent by itself, has clinically important drug-interaction restrictions, and competes with ritonavir and newer long-acting HIV treatment strategies. The product’s durable value is tied to combination-product sales, intellectual property around formulations and regimens, and continued use in patients receiving boosted protease-inhibitor therapy.
What is Tybost and how does cobicistat work?
Tybost contains cobicistat, a mechanism-based inhibitor of cytochrome P450 3A, particularly CYP3A. It increases exposure to coadministered antiretroviral agents that are metabolized by CYP3A. Tybost has no direct antiviral activity against HIV-1 and is not used as a complete HIV treatment regimen.
The FDA-approved Tybost indications are:
| Product |
Active ingredient |
FDA role |
| Tybost |
Cobicistat |
Pharmacokinetic enhancer |
| Tybost plus Reyataz |
Cobicistat plus atazanavir |
Boosted HIV regimen |
| Tybost plus Prezista |
Cobicistat plus darunavir |
Boosted HIV regimen |
| Stribild |
Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate |
Complete HIV regimen |
| Genvoya |
Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide |
Complete HIV regimen |
| Symtuza |
Darunavir, cobicistat, emtricitabine, tenofovir alafenamide |
Complete HIV regimen |
Tybost is administered with food when used with atazanavir or darunavir. The label includes warnings concerning drug interactions, renal monitoring, hyperbilirubinemia with atazanavir, and the risk of reduced antiretroviral exposure when cobicistat is used incorrectly. Cobicistat can increase serum creatinine by inhibiting tubular secretion without necessarily reducing true glomerular filtration rate, although renal injury remains a clinical concern in some combinations. (U.S. Food and Drug Administration [FDA], 2023a)
What clinical trials supported Tybost approval?
Tybost’s development program focused on showing that cobicistat could provide pharmacokinetic boosting comparable to ritonavir.
Cobicistat versus ritonavir with atazanavir
The principal evidence supported cobicistat as a booster for atazanavir. A randomized Phase 3 study compared cobicistat-boosted atazanavir with ritonavir-boosted atazanavir, each combined with emtricitabine and tenofovir disoproxil fumarate. Virologic suppression at Week 48 was comparable between the treatment groups.
The trial established that cobicistat could substitute for ritonavir in a standard boosted atazanavir regimen. The main clinical differentiation was formulation and tolerability rather than a new antiviral mechanism. Cobicistat did not remove the interaction profile associated with CYP3A inhibition.
Cobicistat versus ritonavir with darunavir
A second development pathway evaluated cobicistat with darunavir. The FDA approved Tybost for use with darunavir 800 mg in adults without darunavir-associated resistance substitutions. Clinical findings supported pharmacokinetic comparability and virologic efficacy when cobicistat was used instead of ritonavir. (FDA, 2023a)
Fixed-dose combination trials
Cobicistat became commercially more important through complete-regimen products:
- Stribild combined cobicistat with elvitegravir, emtricitabine and tenofovir disoproxil fumarate.
- Genvoya replaced tenofovir disoproxil fumarate with tenofovir alafenamide, reducing certain renal and bone exposure concerns.
- Symtuza combined cobicistat-boosted darunavir with emtricitabine and tenofovir alafenamide.
These products generated more meaningful clinical and commercial value than standalone Tybost. Their trials focused on noninferiority, virologic suppression, treatment-naive patients and switch populations rather than cobicistat as an independent therapeutic.
Are there active Tybost clinical trials?
There is no major late-stage development program aimed at expanding Tybost as a standalone medicine. Cobicistat-related trials are more likely to appear in studies of fixed-dose combinations, treatment switches, drug interactions or HIV treatment strategies.
The clinical-trial outlook has three components:
| Development area |
Current relevance |
| Standalone Tybost efficacy |
Low; cobicistat has no direct antiviral activity |
| Boosted darunavir regimens |
Established use, with continued clinical relevance |
| Fixed-dose combinations |
Primary source of ongoing commercial and clinical value |
| Long-acting HIV therapy |
Structural competitive pressure against daily oral boosters |
| Drug-interaction studies |
Ongoing medical need because cobicistat affects CYP3A substrates |
ClinicalTrials.gov records should be interpreted by intervention and sponsor because a search for “cobicistat” captures completed studies, combination products and pharmacokinetic investigations, not only Tybost-branded development. (National Library of Medicine, 2024)
What is the FDA regulatory status of Tybost?
Tybost received FDA approval in September 2014 under NDA 203094 for use as a pharmacokinetic enhancer with atazanavir or darunavir in adults with HIV-1 infection. The product is also approved in Europe and other major markets under regional regulatory frameworks.
The regulatory position is mature:
| Milestone |
Date |
| FDA approval of Tybost |
September 2014 |
| Genvoya FDA approval |
November 2015 |
| Prezcobix FDA approval |
January 2015 |
| Symtuza FDA approval |
July 2018 |
| Current regulatory category |
Approved HIV pharmacokinetic enhancer |
Tybost is not a complete antiretroviral regimen. Prescribing information requires administration with another active HIV medicine and includes contraindications for drugs with serious or life-threatening interactions. (FDA, 2023a)
What is the Orange Book status of Tybost?
Tybost is listed in the FDA Orange Book under cobicistat and its approved NDA. The relevant commercial question is less whether standalone Tybost remains protected and more whether Gilead’s combination products retain enforceable formulation, composition, process or method-of-use patents.
Orange Book exposure can involve:
- The standalone cobicistat product.
- Fixed-dose elvitegravir/cobicistat/emtricitabine/tenofovir products.
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide.
- Method-of-use claims covering administration with specific antiretroviral agents.
- Formulation and dosage-form claims.
- Pediatric or dosing-related claims where listed.
Patent listings and expiration dates can change through patent-term adjustment, pediatric extensions, reissued patents, delisting and litigation outcomes. The FDA Orange Book remains the controlling source for currently listed patents and approved products. (FDA, 2024a)
When does Tybost lose exclusivity?
Tybost’s primary regulatory exclusivity period has expired. The product was approved in 2014, and its five-year new chemical entity exclusivity period ended in 2019. This does not mean that every cobicistat-containing product became immediately vulnerable to generic competition because patent coverage and product-specific regulatory requirements remain separate issues.
The commercial exclusivity timeline is:
| Protection type |
Tybost position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not the principal protection mechanism |
| Standalone product patent protection |
Dependent on listed and unlisted patent scope |
| Combination-product patent protection |
More commercially important |
| Pediatric exclusivity |
Product-specific and must be verified against current FDA records |
| Regulatory exclusivity for newer combinations |
Separate from standalone Tybost |
Standalone generic entry would require an ANDA applicant to address the listed patents and demonstrate pharmaceutical equivalence. A generic applicant could file a Paragraph IV certification against listed patents and trigger patent litigation if the sponsor sues within the statutory period.
What patents protect Tybost and cobicistat combinations?
Cobicistat-related protection has historically included composition-of-matter, salt, formulation, combination and method-of-use claims. The strongest commercial barriers have generally been associated with combination products rather than the standalone booster.
Composition and formulation patents
Potentially relevant claim categories include:
- Cobicistat chemical composition and stereochemical forms.
- Pharmaceutical compositions containing cobicistat with a protease inhibitor.
- Solid oral dosage forms.
- Tablet formulations containing cobicistat and tenofovir alafenamide.
- Stabilized formulations with specified excipients.
- Manufacturing processes and crystalline forms.
Method-of-use patents
Method claims may cover:
- Boosting atazanavir exposure with cobicistat.
- Boosting darunavir exposure with cobicistat.
- Administration of complete HIV regimens containing cobicistat.
- Dosing in patients with specified renal or treatment histories.
Geographic coverage
The protection landscape differs by jurisdiction:
| Region |
Main legal pathway |
| United States |
Orange Book listings, ANDA Paragraph IV litigation and patent-term adjustment |
| European Union |
National validation of European patents, SPC analysis and national litigation |
| Canada |
Patent Register and notice-of-allegation process |
| Japan |
Patent term and generic approval under PMDA rules |
| Emerging markets |
Local patentability, compulsory licensing and regulatory-linkage differences |
A generic applicant may clear one product while remaining blocked from another. For example, a pathway to standalone cobicistat does not automatically establish freedom to market a fixed-dose product containing darunavir or tenofovir alafenamide.
Which companies are challenging Tybost or cobicistat products?
Generic competition is likely to emerge through product-specific ANDA or regional generic filings rather than a single global challenge to “Tybost.” Potential challengers include large generic manufacturers with HIV portfolios, including Teva, Viatris, Sandoz, Dr. Reddy’s Laboratories, Cipla, Aurobindo and Sun Pharma. The presence of a company in the HIV generic market does not establish that it has filed an application against Tybost or a specific Gilead combination.
The principal competitive threat is not a direct substitute for cobicistat alone. It is a combination of:
- Generic boosted protease-inhibitor regimens.
- Generic versions of older fixed-dose products.
- Ritonavir-based regimens.
- Unboosted integrase-inhibitor regimens.
- Long-acting cabotegravir and rilpivirine.
What patent litigation and settlement agreements affect Tybost?
Cobicistat-related risk is linked to broader Gilead HIV patent litigation, particularly disputes involving Stribild, Genvoya, Symtuza, elvitegravir and tenofovir alafenamide. Litigation may involve patent validity, infringement, Orange Book listing practices, obviousness, enablement and the scope of fixed-dose combination claims.
Settlement agreements in HIV products commonly define:
- Earliest authorized generic entry.
- Launch dates by product and jurisdiction.
- Restrictions on manufacturing or sourcing.
- Licenses to specified patents.
- Confidential commercial terms.
- Treatment of later-issued patents.
A settlement involving one Gilead combination does not necessarily authorize launch of another cobicistat product. The legal analysis must be performed at the NDA, formulation and patent-claim level.
How strong is the Tybost patent estate?
The standalone Tybost estate is weaker than the broader cobicistat combination estate because the active ingredient is mature, the primary regulatory exclusivity period has ended, and the medicine has no independent antiviral indication.
The estate remains commercially relevant where claims cover:
- A differentiated fixed-dose composition.
- Tenofovir alafenamide-containing tablets.
- Darunavir/cobicistat combinations.
- Specific dosage strengths.
- Manufacturing processes that are difficult to design around.
- Method-of-use claims tied to approved dosing.
Patent strength is moderate for the standalone product and higher for selected combination products, but it declines as core patents expire and generic manufacturers develop alternative formulations.
What generic entry risks exist for Tybost?
The highest-risk scenario is an initial generic launch of standalone cobicistat after patent clearance, followed by product-specific challenges to older cobicistat-containing regimens.
Generic launch scenarios
| Scenario |
Timing logic |
Commercial effect |
| Standalone cobicistat launch |
After listed-patent clearance or settlement |
Limited direct erosion because Tybost is a niche booster |
| Generic atazanavir/cobicistat |
Requires product-specific approval and patent clearance |
Pressure on boosted atazanavir use |
| Generic darunavir/cobicistat |
Greater clinical relevance |
Pressure on Prezista-based regimens |
| Generic Genvoya equivalent |
High technical and patent complexity |
Potentially material erosion to the elvitegravir franchise |
| Generic Symtuza equivalent |
High-value target with formulation barriers |
Larger risk to darunavir-based sales |
| Ritonavir substitution |
Already available |
Ongoing price pressure and prescribing flexibility |
The largest threat to Gilead is likely combination-product erosion rather than standalone Tybost substitution.
How does Tybost compare with ritonavir?
| Attribute |
Tybost |
Ritonavir |
| Primary role |
Pharmacokinetic enhancer |
Antiretroviral and pharmacokinetic enhancer |
| Direct HIV activity |
None |
Yes, although rarely used as primary antiviral therapy |
| CYP3A inhibition |
Strong |
Strong |
| Tablet formulation |
Available |
Available in multiple forms |
| Clinical use |
Cobicistat-containing regimens |
Boosted protease inhibitors and other uses |
| Interaction burden |
High |
High |
| Generic availability |
Product-specific |
Broad generic availability |
| Strategic position |
Integrated into Gilead combinations |
Lower-cost established booster |
Cobicistat was developed to provide boosting without ritonavir’s antiviral activity and to support fixed-dose tablet development. Ritonavir retains a cost and availability advantage because of broad generic supply.
What is the Tybost market size and revenue exposure?
Gilead does not generally report standalone Tybost revenue as a separate major commercial segment. Cobicistat sales are embedded in combination products and therefore cannot be cleanly isolated from public company reporting.
The relevant revenue pools are Gilead’s HIV products:
- Biktarvy, which does not contain cobicistat.
- Genvoya, which contains cobicistat.
- Symtuza, which contains cobicistat.
- Stribild, an older cobicistat-containing regimen.
- Odefsey and Descovy, which do not contain cobicistat.
- Prezcobix, marketed with darunavir and cobicistat.
Gilead reported total HIV product sales of approximately $18.1 billion in 2023, driven principally by Biktarvy and other products that do not contain cobicistat. (Gilead Sciences, 2024) This means total Gilead HIV revenue materially overstates Tybost-linked exposure.
Market projection
A reasonable base-case market view is:
| Period |
Standalone Tybost outlook |
Cobicistat-containing franchise outlook |
| 2024-2026 |
Flat to declining |
Stable to modest decline |
| 2027-2030 |
Accelerated erosion if generic entry occurs |
Decline led by aging regimens and patent expiry |
| 2031 onward |
Mature generic or low-value branded niche |
Residual use in boosted darunavir and selected fixed-dose regimens |
The standalone Tybost market is likely to remain a small fraction of Gilead’s HIV franchise. A scenario range of flat to low-single-digit annual decline before meaningful generic entry, followed by an approximate 30% to 60% revenue reduction within three years of direct generic competition, is commercially reasonable for a mature oral booster. Combination products may experience slower erosion where patent barriers, physician familiarity and regimen-specific clinical demand remain strong.
These projections are more sensitive to patent settlements, generic filing dates and Gilead’s pricing strategy than to new Tybost clinical data.
What manufacturing and intellectual-property barriers affect generic cobicistat?
Cobicistat itself is a small molecule, so the manufacturing barrier is lower than for biologics. The more important challenges involve finished-dose formulation and combination-tablet development.
Key barriers include:
- Reproducing dissolution performance across multiple active ingredients.
- Managing chemical stability in fixed-dose tablets.
- Establishing bioequivalence for highly variable pharmacokinetic regimens.
- Demonstrating compatibility with tenofovir alafenamide or darunavir.
- Designing around formulation patents.
- Meeting FDA requirements for drug-drug interaction labeling.
- Securing active pharmaceutical ingredient supply.
- Establishing a complete product-specific patent position.
These barriers can delay launch even after composition-of-matter protection has expired.
What is the competitive outlook for Tybost?
Tybost’s competitive position is defensive rather than expansionary. The product remains useful in boosted protease-inhibitor therapy, but modern HIV prescribing increasingly favors high-barrier integrase inhibitors, once-daily complete regimens and long-acting injectable therapy.
The principal alternatives are:
- Ritonavir-boosted darunavir.
- Unboosted dolutegravir-based regimens.
- Bictegravir-based Biktarvy.
- Cabotegravir/rilpivirine long-acting therapy.
- Generic antiretroviral combinations.
Cobicistat remains relevant where boosted darunavir is clinically preferred, where a fixed-dose combination improves adherence, or where treatment history limits other options. Its strategic value is concentrated in regimen architecture, not independent market demand.
Key Takeaways
- Tybost is cobicistat, a pharmacokinetic enhancer approved for use with atazanavir or darunavir.
- Its pivotal clinical evidence established pharmacokinetic and virologic comparability with ritonavir-based regimens.
- Standalone Tybost development is mature; ongoing value comes from Genvoya, Symtuza, Stribild and Prezcobix.
- FDA new chemical entity exclusivity expired in 2019.
- Patent risk is more significant for fixed-dose combinations than for standalone cobicistat.
- Generic entry would likely have limited direct impact on Tybost but could materially affect cobicistat-containing combination products.
- Gilead does not separately disclose a large standalone Tybost revenue stream.
- The long-term market outlook is flat to declining, with greater erosion after product-specific generic approvals.
- Ritonavir, integrase-inhibitor regimens and long-acting HIV therapy are the principal competitive pressures.
- Formulation, bioequivalence and combination-product patents remain the main barriers to generic launch.
FAQs
Is Tybost an HIV treatment by itself?
No. Tybost has no direct antiviral activity and must be administered with an active antiretroviral regimen.
Does Tybost contain ritonavir?
No. Tybost contains cobicistat. Both drugs inhibit CYP3A and can boost protease-inhibitor exposure, but they are chemically different products.
Is there a generic version of Tybost?
Generic availability depends on jurisdiction, product-specific approvals and remaining patent barriers. A generic version of standalone cobicistat would not automatically authorize a generic version of Genvoya or Symtuza.
Does Biktarvy contain cobicistat?
No. Biktarvy contains bictegravir, emtricitabine and tenofovir alafenamide. It does not require a pharmacokinetic booster.
Why is cobicistat used in Symtuza?
Cobicistat increases darunavir exposure, allowing darunavir to be incorporated into a once-daily fixed-dose HIV regimen with emtricitabine and tenofovir alafenamide.
References
- Gilead Sciences, Inc. (2024). 2023 annual report. https://www.gilead.com
- National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov
- U.S. Food and Drug Administration. (2023a). Tybost (cobicistat) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2014). FDA approves Tybost to boost HIV medicines. https://www.fda.gov
- European Medicines Agency. (2024). Tybost: European public assessment report. https://www.ema.europa.eu
